Celldex Therapeutics, Inc. (CLDX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$27.73

From 52W high−33.88%

Volume1.64M

Market cap$2.33B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$27.73

From 52W high

−33.88%

Volume

1.64M

Market cap

$2.33B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.4x

P/E (TTM)

—

RSI (14)

39.5

MomentumView details →

1D Return

+7.77%

YTD Return

+8.60%

SummaryUpdated Jun 1, 2026

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a biopharmaceutical company founded in 1983 and headquartered in Hampton, New Jersey. The company went public in 1986 and has spent nearly four decades developing innovative antibody-based therapies for cancer and inflammatory diseases. Celldex specializes in creating monoclonal and bispecific antibodies, which are sophisticated protein-based drugs designed to target specific disease mechanisms with high precision. The company operates as a clinical-stage biotechnology firm, meaning its drug candidates are currently undergoing human testing but have not yet received regulatory approval for commercial sale.

Ask drillr about Celldex Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−42.07%

ROA (TTM)

−38.42%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−98.07%

EPS YoY

−44.85%

FCF YoY

−29.09%

Revenue CAGR 3Y

−13.98%

EPS CAGR 3Y

−59.18%

EBITDA YoY

−38.10%

MomentumView details →

1D Return

+7.77%

YTD Return

+8.60%

1Y Return

+6.60%

RSI (14)

39.5

vs 50D SMA

−18.86%

vs 200D SMA

−9.27%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

11.82x

Quick Ratio

11.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.94

EPS Surprise

11.32%

Beats (12Q)

6/12

Next Q EPS Est

−$1.02

Avg Surprise (4Q)

−3.09%

Rev Surprise

−97.01%

Financials snapshotView financials →

Revenue (TTM)

112000.00

Net Income (TTM)

−300.59M

Op. CF (TTM)

−235.57M

Next earningsNov 9, 2026 →

Latest newsMore news →

Celldex Therapeutics announced that its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.28d ago

Celldex Therapeutics reported its Q2 2026 financial results, with revenue of $22,000 and a net loss of $73.5 million.75d ago

Similar companies

Frontage Holdings Corporation01521.HK Viridian Therapeutics, Inc.VRDN 东亚药业605177.SH Precigen, Inc.PGEN Jiangsu Recbio Technology Co., Ltd.02179.HK Day One Biopharmaceuticals, Inc.DAWN Find similar companies →

Latest newsMore news →

Celldex Therapeutics announced that its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.28d ago Celldex Therapeutics reported its Q2 2026 financial results, with revenue of $22,000 and a net loss of $73.5 million.75d ago